354 related articles for article (PubMed ID: 9768527)
21. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
23. Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome.
Hammer J; Phillips SF; Talley NJ; Camilleri M
Aliment Pharmacol Ther; 1993 Oct; 7(5):543-51. PubMed ID: 8280823
[TBL] [Abstract][Full Text] [Related]
24. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
[TBL] [Abstract][Full Text] [Related]
25. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
Maxton DG; Morris J; Whorwell PJ
Aliment Pharmacol Ther; 1996 Aug; 10(4):595-9. PubMed ID: 8853764
[TBL] [Abstract][Full Text] [Related]
26. Tegaserod and other serotonergic agents: what is the evidence?
Chey WD
Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
[TBL] [Abstract][Full Text] [Related]
27. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
Humphrey PP; Bountra C; Clayton N; Kozlowski K
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
[TBL] [Abstract][Full Text] [Related]
28. Alosetron and irritable bowel syndrome.
Mayer EA; Bradesi S
Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
[TBL] [Abstract][Full Text] [Related]
29. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron).
Goldberg PA; Kamm MA; Setti-Carraro P; van der Sijp JR; Roth C
Digestion; 1996; 57(6):478-83. PubMed ID: 8913711
[TBL] [Abstract][Full Text] [Related]
30. Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
Bush TG; Spencer NJ; Watters N; Sanders KM; Smith TK
Am J Physiol Gastrointest Liver Physiol; 2001 Oct; 281(4):G974-83. PubMed ID: 11557518
[TBL] [Abstract][Full Text] [Related]
31. Review article: evaluation of drugs in experimental gut distension models.
Pappas TN; Mangel AW; Lawson C
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():54-6. PubMed ID: 10429741
[TBL] [Abstract][Full Text] [Related]
32. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism.
Zighelboim J; Talley NJ; Phillips SF; Harmsen WS; Zinsmeister AR
Dig Dis Sci; 1995 Apr; 40(4):819-27. PubMed ID: 7720476
[TBL] [Abstract][Full Text] [Related]
33. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
Cremonini F; Delgado-Aros S; Camilleri M
Neurogastroenterol Motil; 2003 Feb; 15(1):79-86. PubMed ID: 12588472
[TBL] [Abstract][Full Text] [Related]
35. Alosetron for irritable bowel syndrome.
Barbehenn E; Lurie P; Wolfe SM
Lancet; 2000 Dec; 356(9246):2009-10. PubMed ID: 11130544
[No Abstract] [Full Text] [Related]
36. 5-HT
El-Ayache N; Galligan JJ
Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G132-G143. PubMed ID: 30359082
[TBL] [Abstract][Full Text] [Related]
37. Alosetron: a new therapy for irritable bowel syndrome.
Kupecz D
Nurse Pract; 2000 Jul; 25(7):95-6, 98-100. PubMed ID: 10916831
[No Abstract] [Full Text] [Related]
38. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone.
Bradette M; Delvaux M; Staumont G; Fioramonti J; Bueno L; Frexinos J
Dig Dis Sci; 1994 Jun; 39(6):1171-8. PubMed ID: 8200249
[TBL] [Abstract][Full Text] [Related]
39. Alosetron in irritable bowel syndrome.
McColl KE
Lancet; 2000 Jul; 356(9224):164-5. PubMed ID: 10963271
[No Abstract] [Full Text] [Related]
40. Distension technique influences the relationship between colonic and rectal hypersensitivity in irritable bowel syndrome.
Ng C; Malcolm A; Hansen R; Kellow JE
Neurogastroenterol Motil; 2006 Mar; 18(3):206-10. PubMed ID: 16487411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
